Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (221-230 of 516) with videos related to

Pageof 52
Sort By:
Blood|October 24, 2002
Prognostic value of angiogenesis in solitary bone plasmacytomaShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaKlaus Podar, Giovanni Tonon, Martin Sattler, et al.
Contemporary Clinical Trials Communications|August 5, 2022
A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncologyRahma Warsame, Joselle Cook, Briant Fruth, et al.
Blood|May 25, 2010
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complicationsGiada Bianchi, Robert A Kyle, Colin L Colby, et al.
Haematologica|July 24, 2025
Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodiesMatthew J Rees, Surendra Dasari, Ellen D McPhail, et al.
Blood Cancer Journal|December 6, 2023
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myelomaAmit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, et al.
British Journal of Haematology|June 2, 2020
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemicEfstathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2013
Reply to S. Girnius et alGiovanni Palladini, Angela Dispenzieri, Morie Gertz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 12, 2013
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratificationLuciano J Costa, Elizabeth J Nista, Francis K Buadi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomicsLiewei Wang, Shaji Kumar, Brooke L Fridley, et al.
Pageof 52

Showing results (221-230 of 516) with videos related to

Sort By:
Pageof 52
Blood|October 24, 2002
Prognostic value of angiogenesis in solitary bone plasmacytomaShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaKlaus Podar, Giovanni Tonon, Martin Sattler, et al.
Contemporary Clinical Trials Communications|August 5, 2022
A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncologyRahma Warsame, Joselle Cook, Briant Fruth, et al.
Blood|May 25, 2010
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complicationsGiada Bianchi, Robert A Kyle, Colin L Colby, et al.
Haematologica|July 24, 2025
Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodiesMatthew J Rees, Surendra Dasari, Ellen D McPhail, et al.
Blood Cancer Journal|December 6, 2023
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myelomaAmit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, et al.
British Journal of Haematology|June 2, 2020
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemicEfstathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2013
Reply to S. Girnius et alGiovanni Palladini, Angela Dispenzieri, Morie Gertz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 12, 2013
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratificationLuciano J Costa, Elizabeth J Nista, Francis K Buadi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomicsLiewei Wang, Shaji Kumar, Brooke L Fridley, et al.
Pageof 52